---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-010412"
form_type: "8-K"
ticker: "CYDY"
cik: "0001175680"
company_name: "CytoDyn Inc."
filed_at: "2023-05-24T23:59:59+00:00"
generated_at: "2026-06-14T15:42:14.725271+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CytoDyn president takes medical leave; CFO assumes interim role; new CMO and advisor appointed

## Summary
- Dr. Cyrus Arman, President, takes medical leave; Antonio Migliarese (CFO) named interim principal executive officer.
- Dr. Melissa Palmer appointed interim Chief Medical Officer; she has NASH and liver disease expertise.
- Dr. Salah Kivlighn joins as clinical and strategic advisor; 30+ years industry experience including at Merck and Kite Pharma.
- Company priorities: lift HIV clinical hold on leronlimab, advance NASH phase 2b trial, explore strategic opportunities.

## SEC filing metadata
- accession: 0001558370-23-010412
- form_type: 8-K
- ticker: CYDY
- cik: 0001175680
- company_name: CytoDyn Inc.
- filed_at: 2023-05-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175680/000155837023010412/0001558370-23-010412-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175680/000155837023010412/cydy-20230518x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-010412
- JSON: https://secwatch.observer/filing/0001558370-23-010412.json
- Plain text: https://secwatch.observer/filing/0001558370-23-010412.txt

## Key facts
- Executive change
  Antonio Migliarese was appointed as acting principal executive officer at CytoDyn Inc..
  - Action: appointed
  - Role: acting principal executive officer
  source text: On May 18, 2023, the Company’s Board of Directors appointed Antonio Migliarese as acting principal executive officer of the Company on an interim basis.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175680/000155837023010412/0001558370-23-010412-index.htm
- Executive change
  Dr. Cyrus Arman changed role as President at CytoDyn Inc..
  - Action: taking a medical leave of absence
  - Role: President
  source text: Dr. Cyrus Arman, President of CytoDyn Inc. (the “Company”) and the Company’s principal executive officer, recently informed the Company that he will be taking a medical leave of absence.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175680/000155837023010412/0001558370-23-010412-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.